Microarray patches for managing infections at a global scale

被引:9
作者
Anjani, Qonita Kurnia [1 ,2 ]
Bin Sabri, Akmal Hidayat [1 ]
Hutton, Aaron J. [1 ]
Carcamo-Martinez, Alvaro [3 ]
Wardoyo, Luki Ahmadi Hari [4 ]
Mansoor, Alvanov Zpalanzani [4 ]
Donnelly, Ryan F. [1 ,5 ]
机构
[1] Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Univ Megarezky, Fak Farm, Jl Antang Raya 43, Makassar 90234, Indonesia
[3] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach An Der Riss, Germany
[4] Inst Teknol Bandung, Fak Seni Rupa dan Desain, Jl Ganesa 10, Bandung 40132, Indonesia
[5] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Pharmaceut Technol, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
基金
英国惠康基金;
关键词
Microarray patch; Infectious disease; Tuberculosis; Skin infection; Malaria; MRSA; Covid-19; RESISTANT STAPHYLOCOCCUS-AUREUS; HYDROGEL-FORMING MICRONEEDLES; TRANSDERMAL DELIVERY; INFLUENZA VACCINE; TUBERCULOSIS TREATMENT; INTESTINAL MICROBIOTA; DRUG; SKIN; MANAGEMENT; EFFICACY;
D O I
10.1016/j.jconrel.2023.05.038
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Since the first patent for micro array patches (MAPs) was filed in the 1970s, research on utilising MAPs as a drug delivery system has progressed significantly, evidenced by the transition from the simple 'poke and patch' of solid MAPs to the development of bio responsive systems such as hydrogel-forming and dissolving MAPs. In addition to the extensive research on MAPs for improving transdermal drug delivery, there is a growing interest in using these devices to manage infectious diseases. This is due to the minimally invasive nature of this drug delivery platform which enable patients to self-administer therapeutics without the aid of healthcare pro-fessionals. This review aims to provide a critical analysis on the potential utility of MAPs in managing infectious diseases which are still endemic at a global scale. The range of diseases covered in this review include tuber-culosis, skin infections, malaria, methicillin-resistant Staphylococcus aureus infections and Covid-19. These dis-eases exert a considerable socioeconomic burden at a global scale with their impact magnified in low-and middle-income countries (LMICs). Due to the painless and minimally invasive nature of MAPs application, this technology also provides an efficient solution not only for the delivery of therapeutics but also for the administration of vaccine and prophylactic agents that could be used in preventing the spread and outbreak of emerging infections. Furthermore, the ability of MAPs to sample and collect dermal interstitial fluid that is rich in disease-related biomarkers could also open the avenue for MAPs to be utilised as a minimally invasive biosensor for the diagnosis of infectious diseases. The efficacy of MAPs along with the current limitations of such strategies to prevent and treat these infections will be discussed. Lastly, the clinical and translational hurdles associated with MAP technologies will also be critically discussed.
引用
收藏
页码:97 / 115
页数:19
相关论文
共 177 条
  • [1] Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis
    Ahmad, Suhail
    Mokaddas, Eiman
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2014, 7 (02) : 75 - 91
  • [2] Metronidazole nanosuspension loaded dissolving microarray patches: An engineered composite pharmaceutical system for the treatment of skin and soft tissue infection
    Anjani, Qonita Kurnia
    Bin Sabri, Akmal Hidayat
    Dominguez-Robles, Juan
    Moreno-Castellanos, Natalia
    Utomo, Emilia
    Wardoyo, Luki Ahmadi Hari
    Larraneta, Eneko
    Donnelly, Ryan F.
    [J]. BIOMATERIALS ADVANCES, 2022, 140
  • [3] Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs
    Anjani, Qonita Kurnia
    Permana, Andi Dian
    Carcamo-Martinez, Alvaro
    Dominguez-Robles, Juan
    Tekko, Ismaiel A.
    Larraneta, Eneko
    Vora, Lalit K.
    Ramadon, Delly
    Donnelly, Ryan F.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2021, 158 : 294 - 312
  • [4] [Anonymous], 2022, LEO PHARM LTS LOHM T
  • [5] [Anonymous], 2016, GLOBAL TRANSDERMAL D
  • [6] [Anonymous], 2023, BURD DIS
  • [7] [Anonymous], 2023, THES AR TOP 10 EM TE
  • [8] [Anonymous], 2023, 1 EVER CLIN TRIAL MI
  • [9] [Anonymous], 2023, TRIAL VTANG 2 85 M D
  • [10] The role of evolution in the emergence of infectious diseases
    Antia, R
    Regoes, RR
    Koella, JC
    Bergstrom, CT
    [J]. NATURE, 2003, 426 (6967) : 658 - 661